| Item Type | Name |
|
Concept
|
Complementary Therapies
|
|
Concept
|
Combined Modality Therapy
|
|
Concept
|
Drug Therapy
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Pharmacy and Therapeutics Committee
|
|
Concept
|
Treatment Refusal
|
|
Concept
|
Salvage Therapy
|
|
Concept
|
Therapies, Investigational
|
|
Concept
|
Treatment Outcome
|
|
Concept
|
Therapeutic Human Experimentation
|
|
Concept
|
Therapeutic Equivalency
|
|
Concept
|
Molecular Targeted Therapy
|
|
Concept
|
Treatment Failure
|
|
Concept
|
Genetic Therapy
|
|
Concept
|
Withholding Treatment
|
|
Academic Article
|
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
|
|
Academic Article
|
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support.
|
|
Academic Article
|
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
|
|
Academic Article
|
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
|
|
Academic Article
|
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
|
|
Academic Article
|
Keratoacanthomas and skin neoplasms associated with suramin therapy.
|
|
Academic Article
|
Mineralocorticoid insufficiency due to suramin therapy.
|
|
Academic Article
|
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.
|
|
Academic Article
|
Therapeutic relevance of pharmacokinetics and pharmacodynamics.
|
|
Academic Article
|
Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.
|
|
Academic Article
|
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.
|
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
|
|
Academic Article
|
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.
|
|
Academic Article
|
Evaluation of neuropathy in patients on suramin treatment.
|
|
Academic Article
|
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
|
|
Academic Article
|
Promising new agents in oncologic treatment.
|
|
Academic Article
|
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.
|
|
Academic Article
|
Oral chemotherapy: rationale and future directions.
|
|
Academic Article
|
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
|
|
Academic Article
|
Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia.
|
|
Academic Article
|
Gazing into a crystal ball-cancer therapy in the post-genomic era.
|
|
Academic Article
|
Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis.
|
|
Academic Article
|
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
|
|
Academic Article
|
Rationale for phase I study of UFT plus leucovorin and oral JM-216.
|
|
Academic Article
|
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
|
|
Academic Article
|
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
|
|
Academic Article
|
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
|
|
Academic Article
|
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
|
|
Academic Article
|
Pharmacogenetics: a tool for individualizing antineoplastic therapy.
|
|
Academic Article
|
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
|
|
Academic Article
|
Troxacitabine in patients with refractory leukemia.
|
|
Academic Article
|
Pharmacogenetics in cancer treatment.
|
|
Academic Article
|
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
|
|
Academic Article
|
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
|
|
Academic Article
|
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
|
|
Academic Article
|
Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia.
|
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
|
Academic Article
|
Pharmacogenomics: road to anticancer therapeutics nirvana?
|
|
Academic Article
|
Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.
|
|
Academic Article
|
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
|
|
Academic Article
|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
|
|
Academic Article
|
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
|
|
Academic Article
|
Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
|
|
Academic Article
|
UGT pharmacogenomics: implications for cancer risk and cancer therapeutics.
|
|
Academic Article
|
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
|
|
Academic Article
|
Pharmacokinetic variability of anticancer agents.
|
|
Academic Article
|
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
|
|
Academic Article
|
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
|
|
Academic Article
|
Personalized medicine: building the GPS to take us there.
|
|
Academic Article
|
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
|
|
Academic Article
|
Interpreting disparate responses to cancer therapy: the role of human population genetics.
|
|
Academic Article
|
The pharmacogenetics research network: from SNP discovery to clinical drug response.
|
|
Academic Article
|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
|
|
Academic Article
|
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
|
|
Academic Article
|
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
|
|
Academic Article
|
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
|
|
Academic Article
|
Recent advances in the treatment of hairy-cell leukemia.
|
|
Academic Article
|
Sequential treatment of hairy cell leukemia: a new role for interferon.
|
|
Academic Article
|
Hairy cell leukemia. Current management.
|
|
Academic Article
|
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
|
|
Academic Article
|
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
|
|
Academic Article
|
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
|
|
Academic Article
|
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
|
|
Academic Article
|
Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
|
|
Academic Article
|
Evaluating the activity of temsirolimus in neuroendocrine cancer.
|
|
Academic Article
|
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.
|
|
Academic Article
|
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
|
|
Academic Article
|
A phase I study of continuous infusion cilengitide in patients with solid tumors.
|
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
|
Academic Article
|
Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?
|
|
Academic Article
|
The investigational drug steering committee.
|
|
Academic Article
|
What is the choice of treatment for hairy cell leukemia?
|
|
Academic Article
|
Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.
|
|
Academic Article
|
Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia.
|
|
Academic Article
|
Optimising the design of phase II oncology trials: the importance of randomisation.
|
|
Academic Article
|
Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986.
|
|
Academic Article
|
Changes in peripheral blood and bone marrow specimens following therapy with recombinant alpha 2 interferon for hairy cell leukemia.
|
|
Academic Article
|
Bar the windows but open the door to randomization.
|
|
Academic Article
|
Resampling phase III data to assess phase II trial designs and endpoints.
|
|
Academic Article
|
Treatment of hairy cell leukemia with recombinant alpha 2 interferon.
|
|
Academic Article
|
Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables.
|
|
Academic Article
|
Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia.
|
|
Academic Article
|
Durability of responses to interferon alfa-2b in advanced hairy cell leukemia.
|
|
Academic Article
|
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.
|
|
Academic Article
|
The role of interferon in the treatment of hairy cell leukemia.
|
|
Academic Article
|
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
|
|
Academic Article
|
The treatment of hairy cell leukemia: an update.
|
|
Academic Article
|
Randomized phase II trials: a long-term investment with promising returns.
|
|
Academic Article
|
Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
|
|
Academic Article
|
Sequential therapy with dacarbazine and carmustine: a phase I study.
|
|
Academic Article
|
Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes.
|
|
Academic Article
|
Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring.
|
|
Academic Article
|
Changes in peripheral blood and bone marrow specimens during and after alpha 2b-interferon therapy for hairy cell leukemia.
|
|
Academic Article
|
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
|
|
Academic Article
|
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
|
|
Academic Article
|
Analysis of the yield of phase II combination therapy trials in medical oncology.
|
|
Academic Article
|
Low-dose interferon alfa-2b in the treatment of hairy cell leukemia.
|
|
Academic Article
|
Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity?
|
|
Academic Article
|
Flow cytometry in hairy cell leukemia before and during interferon alfa-2b therapy.
|
|
Academic Article
|
Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-1986.
|
|
Academic Article
|
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
|
|
Academic Article
|
Drug combinations: dangerous liaisons or great expectations?
|
|
Academic Article
|
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
|
|
Academic Article
|
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
|
|
Academic Article
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
|
|
Academic Article
|
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
|
|
Academic Article
|
Measuring response in a post-RECIST world: from black and white to shades of grey.
|
|
Academic Article
|
The role of pharmacogenetics in cancer therapeutics.
|
|
Academic Article
|
Pharmacodynamics in cancer therapy.
|
|
Academic Article
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
|
Academic Article
|
Duration of response after interferon treatment of hairy cell leukemia.
|
|
Academic Article
|
Creating and evaluating genetic tests predictive of drug response.
|
|
Academic Article
|
Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
|
|
Academic Article
|
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
|
|
Academic Article
|
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
|
|
Academic Article
|
Opportunities and challenges in the development of experimental drug combinations for cancer.
|
|
Academic Article
|
Prognostic variables in hairy cell leukemia after splenectomy as initial therapy.
|
|
Academic Article
|
Skeletal complications in hairy cell leukemia: diagnosis and therapy.
|
|
Academic Article
|
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
|
|
Academic Article
|
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
|
|
Academic Article
|
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
|
|
Academic Article
|
Targeted therapies: redefining the primary objective of phase I oncology trials.
|
|
Academic Article
|
Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science.
|
|
Academic Article
|
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.
|
|
Academic Article
|
Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.
|
|
Academic Article
|
Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials.
|
|
Academic Article
|
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).
|
|
Academic Article
|
Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.
|
|
Academic Article
|
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
|
|
Academic Article
|
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
|
|
Academic Article
|
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
|
|
Academic Article
|
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
|
|
Academic Article
|
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
|
|
Academic Article
|
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
|
|
Academic Article
|
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
|
|
Academic Article
|
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
|
|
Academic Article
|
Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.
|
|
Academic Article
|
Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew.
|
|
Academic Article
|
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
|
|
Academic Article
|
Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19.
|
|
Academic Article
|
COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19.
|
|
Academic Article
|
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
|
|
Academic Article
|
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments.
|
|
Academic Article
|
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
|
|
Academic Article
|
Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics.
|
|
Academic Article
|
Combination therapy patents: a new front in evergreening.
|
|
Academic Article
|
Applicability of Pharmacogenomically Guided Medication Treatment during Hospitalization of At-Risk Minority Patients.
|
|
Academic Article
|
In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
|
|
Academic Article
|
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
|
|
Grant
|
CANCER AND LEUKEMIA GROUP B--PET COMMITTEE
|
|
Academic Article
|
Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.
|
|
Academic Article
|
An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States.
|
|
Academic Article
|
Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy.
|
|
Academic Article
|
Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer.
|
|
Academic Article
|
Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of Preemptive CYP2D6 Genotyping in Cancer Palliative Care.
|
|
Academic Article
|
Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy.
|
|
Grant
|
Phase I Clinical Trials of Anti-Cancer Agents
|
|
Grant
|
PAAR-Pharmacogenomics of Anticancer Agents Research Group
|
|
Grant
|
Experimental Therapeutics: Clinical Trials Network with Phase I Emphasis
|
|
Grant
|
Clinical Therapeutics
|